Probatebeta
Target

MAOB

Amine oxidase [flavin-containing] B

As of the edition of 20 October 2026, MAOB (amine oxidase [flavin-containing] B, UniProt P27338) has 15 drugs tested at it and 17 companies on the list, 2 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P27338
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
57
Disease areas
Nervous system; Mental health; Chemically induced; Cancer; Urinary and reproductive; Nutrition and metabolism; Immune system; Blood and lymph
Registered trials of its drugs
124

Drugs at this target

StatusCount
Marketed8
Active1
Went quiet3
Withdrawn from market3
Total15
DrugStatusFurthest phaseUS protection
RasagilineMarketedPhase 4Ends 2027
SelegilineMarketedPhase 4none listed
SafinamideMarketedPhase 4Ends 2028
TranylcypromineMarketedPhase 4none listed
PhenelzineMarketedPhase 4none listed
RO4602522Went quietPhase 2none listed
EVT 302Went quietPhase 2none listed
KDS2010ActivePhase 2none listed
RalfinamideWent quietPhase 3none listed
IsocarboxazidMarketedPhase 1none listed
IproniazidMarketedNo phase statednone listed
MebanazineWithdrawn from marketNo phase statednone listed

12 of 15 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A2
Route B6
Engaged1
Undetermined8
Total on the list17
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
TevaRoute B
Meiji Seika PharmaRoute B

The other 14 companies at MAOB

In the product

17 companies in all; 14 are not named here, and no score is.

See the 17 companies at MAOB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at MAOB

Other targets in nervous system

Companies holding approvals at MAOB